Avacta Group Bolsters Board with Strategic New Appointments

PUBLISHED: 28 May 2025 @ 17:57 | Comments (0) | More info about Fiona Craig

Avacta Group plc (LSE:AVCT) has strengthened its leadership team with the addition of David Bryant and Richard Hughes as Non-Executive Directors. These appointments bring a wealth of experience from the pharmaceutical sector and financial markets, aligning with Avacta’s ongoing evolution into a focused therapeutics company. The move is aimed at accelerating the development of its innovative drug pipeline powered by the proprietary preCISION® platform and maximizing long-term value for shareholders.

About Avacta Group plc

Avacta Therapeutics is a clinical-stage biopharmaceutical company dedicated to pioneering cancer treatments. Its core technology, the preCISION® platform, enables targeted delivery of powerful anti-cancer agents directly to tumor sites, helping to reduce harm to healthy cells and improve treatment efficacy. The company’s pipeline features peptide and Affimer® drug conjugates, which are designed to offer advantages over conventional therapeutic approaches.

Average Daily Trading Volume: 1,921,572
Technical Market Signal: Sell
Current Valuation: £106.3 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.